300x60 Goldinvest Banner

Khiron Life Science

  • TORONTO, Oct. 25, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that, after a successful first year in the Colombian market, the Company adds another significant milestone: its first import of Kuida cosmetic products into the United States. With this first shipment complete, Kuida has become the first Colombian brand to introduce legal CBD products in the US market.

    • Kuida is the first CBD skincare portfolio of products launched in Colombia from a federally approved cannabis company
    • Company has fulfilled E.U. cosmetic product regulatory requirements for seven Kuida® products
    • Initial UK import anticipated for Q4 2019
    • Company has received a "no objection" letter from TSXV for distribution of the Kuida products in the UK
    • UK skincare market estimated at US$3.8 billion in 2018 (Source: Euromonitor)

    TORONTO, Oct. 15, 2019 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today it has completed the EU cosmetic regulatory process for seven Kuida products, and has received a "no objection" letter from TSXV with respect to distribution of these products in the UK.

  • TORONTO, Sept. 4, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has commenced construction of a 9,800 m2(105,486 sq.ft) cultivation and processing facility in Juan Lacaze, Uruguay. With a production capacity of 17 tons per year, the Company's investment in this state-of-the-art facility represents a significant increase in Khiron's total production capacity, strengthening its ability to export and supply cannabis to key international markets, including Brazil and Europe. Construction is underway and is scheduled for completion in mid Q3 2020.

  • - Distribution agreement with Grupo Éxito includes initial Kuida presence in 5 key market Éxito WOW concept stores and 16 Éxito traditional format stores with a potential expansion planned across Colombia.
    - Grupo Éxito has a multinational retail presence in Colombia, Brazil, Argentina and Uruguay and operates 1,533 stores.
    - Kuida to be introduced as key addition to the retailer's cosmetics products category, with experience centres and consultants in each Éxito WOW store to support sales and brand awareness.
    - Accelerates Company's multi-channel brand distribution strategy targeting U.S. $7.9 billion Latin American skincare market. (source: Euromonitor)
    - Grupo Éxito is a Colombian retail leader with a market share of 40%. (Source: Nielsen, February 2019)

  • TORONTO, May 29, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce today its addition to the MJ ETFMG Alternative Harvest ETF (NYSE:MJ) (the "Fund"), a fund with approximately US$1.22 billion in assets currently under management. This represents an important development for the Company as it advances its strategy as a Latin American cannabis company with global growth.

  • TORONTO, April 17, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has appointed Mr. Larry Holifield as the company's Security and Compliance Director, Mexico. Mr. Holifield, formerly a senior executive with the U.S. Drug Enforcement Administration ("DEA") with responsibility for Mexico and Central America, will play a key role as the Company builds out its operations and stakeholder relationships in the fast-developing Mexico cannabis industry.

  • Damit ist das auch erledigt: Wie die kanadische Cannabisgesellschaft Khiron Life Sciences (TSX-V KHRN / WKN A2JMZC) gestern Nachmittag bekannt gab, war die Vorverlegung des Ausübungsdatums von Warrants mit einem Ausübungspreis von 1,20 CAD auf den 14. November sehr erfolgreich. Dem Unternehmen floss aus der Ausübung der Warrants ein zweistelliger Millionenbetrag zu.

  • Khiron Life Science (TSX-V KHRN) will hoch hinaus. In Kolumbien vergrößert die Gesellschaft ihre Anbaufläche für medizinisches Cannabis stark, wir berichteten. Nun stehen die Nordamerikaner vor einer Übernahme: Mit dem Kauf des stark wachsenden Latin American Institute of Neurology and the Nervous System, kurz ILANS, will sich Khiron Life Sciences millionenschwere Absatzmärkte für die eigenen Cannabis-basierten Produkte sichern.

  • Das ist ein Knaller! Erst gestern hatten wir den Lesern von GOLDINVEST.de die in Toronto gelistet Khiron Life Science (TSX-V KHRN) vorgestellt und schon heute, nach einer Handelsaussetzung, legt das Unternehmen mit einer spektakulären Personalie nach! Niemand geringeres als der ehemalige Präsident Mexikos Vicente Fox stößt zum Team des angehenden Produzenten medizinischen Marihuanas.

Wir setzen Cookies zum Betrieb und zur Sicherheit der Seite ein, aber auch Dienste Dritter setzen Cookies zum Webtracking bzw. Marketing.
Hinweise zum Datenschutz, Dienste Dritter und Widerspruch finden Sie in unserer Datenschutzerklärung